SCHEMBL17618434

SCHEMBL17618434

Cn1cc2cc(NC(=O)N3c4nc(-c5cccc(Cl)c5)ccc4N4CC[C@H]3C4)ccc2n1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAOA P21397 3/20 0.40
▸ MAOB P27338 3/20 0.40
▸ IRAK4 Q9NWZ3 5/20 0.39
▸ MEN1 O00255 1/20 0.38
▸ CYP1A2 P05177 1/20 0.38
▸ CYP2D6 P10635 1/20 0.38
▸ MAPT P10636 1/20 0.38
▸ CYP2C9 P11712 1/20 0.38
▸ CYP2C19 P33261 1/20 0.38
▸ KMT2A Q03164 1/20 0.38
▸ MCL1 Q07820 1/20 0.38
▸ MAT2A P31153 2/20 0.37
▸ CNR1 P21554 1/20 0.36
▸ F11 P03951 4/20 0.36
▸ KLKB1 P03952 3/20 0.36
▸ KDM4E B2RXH2 1/20 0.36
▸ NOTUM Q6P988 1/20 0.36
▸ PDE4A P27815 1/20 0.35
▸ PDE4B Q07343 1/20 0.35
▸ PDE4C Q08493 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17618429 0.86 LRRK2 (0.40) IRAK4MEN1CYP1A2CYP2D6MAPT
SCHEMBL16238356 0.86 NOTUM (0.38) MAOAMAOBIRAK4MAT2AKDM4E
SCHEMBL17618439 0.83 RAB9A (0.39) MEN1CYP1A2CYP2D6MAPTCYP2C9
SCHEMBL17618437 0.83 CNR2 (0.39) MEN1CYP1A2CYP2D6MAPTCYP2C9
SCHEMBL16754329 0.82 NOTUM (0.37) MAOAMAOBIRAK4MAT2AKDM4E
SCHEMBL17618428 0.81 TSHR (0.46) MAPTCNR1
SCHEMBL17618433 0.81 GRM5 (0.38) MEN1CYP1A2CYP2D6MAPTCYP2C9
SCHEMBL19670176 0.79 CNR1 (0.36) MEN1CYP1A2CYP2D6MAPTCYP2C9
SCHEMBL17618432 0.79 CNR1 (0.36) MEN1CYP1A2CYP2D6MAPTCYP2C9
SCHEMBL17618507 0.79 CNR1 (0.36) MEN1CYP1A2CYP2D6MAPTCYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10590135-B2 Substituted bridged urea analogs as sirtuin modulators GLAXOSMITHKLINE LLC (US) 2020-03-17 — — US disclosed
US-20170355697-A1 SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS GLAXOSMITHKLINE LLC 2017-12-14 — — US disclosed
US-20170355697-A1 SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS GLAXOSMITHKLINE LLC 2017-12-14 — — US disclosed
US-9834558-B2 Substituted bridged urea analogs as sirtuin modulators GLAXOSMITHKLINE LLC (US) 2017-12-05 — — US disclosed
US-9834558-B2 Substituted bridged urea analogs as sirtuin modulators GLAXOSMITHKLINE LLC (US) 2017-12-05 — — US disclosed
US-9765075-B2 Substituted bridged urea analogs as sirtuin modulators GLAXOSMITHKLINE LLC (US) 2017-09-19 — — US disclosed
US-9765075-B2 Substituted bridged urea analogs as sirtuin modulators GLAXOSMITHKLINE LLC (US) 2017-09-19 — — US disclosed
US-20160083386-A1 SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS GLAXOSMITHKLINE LLC 2016-03-24 — — US disclosed
US-20160083386-A1 SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS GLAXOSMITHKLINE LLC 2016-03-24 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160083386-A1 SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS SIRT1, SIRT3, SIRT2 MAOA 1588/4885MAOB 904/4885IRAK4 3208/4885
US-20170355697-A1 SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS SIRT1, SIRT3, SIRT2 MAOA 1519/4885MAOB 985/4885IRAK4 2599/4885
US-10590135-B2 Substituted bridged urea analogs as sirtuin modulators SIRT1, SIRT3, SIRT2 MAOA 1519/4885MAOB 985/4885IRAK4 2599/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback